Good MorningEquity markets tread water on Wednesday ahead of the PPI report on Friday. The report could reinvigorate fear of inflation and the FOMC and spark another decline in the stock market. The S&P 500 is sitting on key support in the form of the 30-day EMA, a move below that could bring on more selling and drive the index down to the October lows.
The PPI report is not expected to show a decline in inflation and that is bad news. At current levels, PPI is supporting consumer-level inflation and may force the FOMC to hike rates by another 75 basis points at the meeting next week. As it is, the CME FedWatch Tool is pricing in a 75% chance the next hike will only be 50 basis points which is bad enough for the economy by itself. Featured:
=== BREAKING === (Behind the Markets) 
|
Stocks | | |
At MarketBeat, we do our best to deliver information about the stocks and stories that are moving the market. But we also want to make sure we give you information about the stocks that you care about the most – because those are the ones that are most likely to be in your portfolio.
While ... Read the Full Story |
|
From Our PartnersMany readers know that Biotech stocks offer tremendous breakout potential when positive news is announced from Phase 1, Phase 2 and Phase 3 trials.
After positive news is announced, some of these little-known companies immediately become overnight sensations…
In particular, there is one Biotech stock that could be getting ready to announce Phase 3 results any day now. | | | | Click Here for Free Stock Report |
|
Stocks | | | Wall Street ended a wobbly day of trading with more losses Wednesday, as a slide in technology companies helped pull stocks lower and Treasury yields fell broadly.
The S&P 500 slipped 0.2%, its fifth straight loss. The Nasdaq composite, which is heavily weighted with tech stocks,... Read the Full Story |
|
Markets | | |
In 1857, John Henry Hopkins Jr. wrote “Three Kings of Orient,” the popular Christmas carol more commonly known today as “We Three Kings.” Based on the Biblical Magi who bore gold, frankincense, and myrrh, the song is about the importance of sacrifice — and belie... Read the Full Story |
|
From Our PartnersU.S. Loses to China in Shocking WAR GAMES
Pentagon says new "living missile" key to winning a future conflict.
Investors stand to reap 35,960% on shares of the small defense contractor that makes powerful new weapon. | | Get the name of the stock here > > > |
|
Stocks | | | Shares are mostly lower in Asia after Wall Street sagged under weakness in tech stocks.
U.S. futures edged lower while oil prices rebounded.
Japan revised upward its GDP data to show the economy contracted less than earlier reported in July-September,... Read the Full Story |
|
Markets | | |
Carvana Co. (NASDAQ: CVNA) shares are down nearly 66% since the beginning of the week on concerns that the company may be headed for bankruptcy. In fact, CVNA stock took a luld (limit up limit down) pause on the morning of December 7.
This came after Bloomberg reported that several of Carv... Read the Full Story |
|
From Our PartnersThis advanced laser system is active in 80 countries around the world. And at the center of this massive market is a small firm in Israel.
Our research shows that anyone who gets in today could see a return of 2,467%. But that's only if the company doesn't get taken over for a fast 300% gain first. | | | | CLICK HERE to see how you can profit from this special opportunity > > > |
|
Markets | | |
Shares of Spotify Technology SA (NYSE: SPOT) were rebounding Wednesday after declining 4.02% Tuesday.
The stock’s price has held above its November 4 low of $69.29. Does that mean we’ve heard the last of its downtrend?
Spotify attempted a rally in the summer, roughly in tandem ... Read the Full Story |
|
Markets | | | Shares were mixed in Europe and Asia ahead of the release Thursday and Friday of U.S. jobless and inflation data.
U.S. futures turned higher and oil prices rebounded.
Investors are watching for data that may yield more insights into inflation’s path ahead and how the Fe... Read the Full Story |
|
Markets | | | Japan’s economy contracted less than previously thought in the last quarter, weathering the country's latest big COVID wave with less damage than had been thought.
The Cabinet Office reported Thursday that the economy shrank at a 0.8% annual rate in July-September. That was better th... Read the Full Story |
|
Markets | | | Lebanon’s once burgeoning banking sector has been hard hit by the country’s historic economic meltdown. It has suffered staggering losses worth tens of billions of dollars and many of the small nation’s lenders now face possible closures or mergers.
Yet bankers have been resisting at... Read the Full Story |
|
Markets | | |
The question of a Fed pivot isn’t if, it’s when because the FOMC can’t continue to hike rates indefinitely. In that scenario, economic activity would grind to a halt and recede, GDP would shrink and the global world order would collapse. No, the FOMC’s mission is to maintai... Read the Full Story |
|
Thursday's Early Bird Stock Of The Day Poseida Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for patients with high unmet medical needs. The company's development candidates for Heme Malignancies includes P-BCMA-ALLO1, which is in Phase I trial to treat patients with relapsed/refractory multiple myeloma; P-CD19CD20-ALLO1, which is in Phase I trial for treating B cell malignancies and other autoimmune diseases; P-BCMACD19-ALLO1, an allogeneic, off-the-shelf CAR-T product candidate in preclinical development for treating multiple myeloma; and P-CD70-ALLO1 under preclinical development to treat hematological indications. It is also involved in the development of P-MUC1C-ALLO1 that is in Phase I trial for treating a range of solid tumors, including breast, colorectal, lung, ovarian, pancreatic, and renal cancers; P-PSMA-ALLO1, an autologous chimeric antigen receptor T cell (CAR-T) product candidate that is in preclinical development for the treatment of patients with metastatic castrate resistant prostate cancer (mCRPC); and P-PSMA-101, an allogeneic CAR-T product candidate under Phase 1 clinical trial for treating mCRPC. In addition, the company engages in the development of P-FVIII-101, a clinical stage liver-directed gene therapy for the in vivo treatment of hemophilia A; P-OTC-101, a clinical stage liver-directed gene therapy for the in vivo treatment of ornithine transcarbamylase deficiency; and P-PAH-101, a clinical stage liver-directed gene therapy for the in vivo treatment of phenylketonuria. It has a research collaboration and license agreement with F. Hoffmann-La Roche Ltd, and Hoffmann-La Roche Inc. The company was incorporated in 2014 and is headquartered in San Diego, California. | | View Today's Stock Pick |
|
